Treatment Of Acute Deep Vein Thrombosis Of The Lower Ext

本研究的目的是评价重组组织型纤溶酶原激活剂(RtPA)溶栓治疗急性深静脉血栓形成的疗效。虽然单纯的抗凝治疗在预防危及生命的肺栓塞方面非常有效，但它不能保护患侧的静脉功能，通常会导致随后几年的静脉炎综合征。这项研究旨在评估这种形式的治疗在恢复下肢静脉功能方面的有效性、安全性和成本。自研究开始以来，已有14名患者接受了治疗。除1例患者外，其余患者均有明显改善。只有两名患者在治疗过程中有证据表明有小的肺血栓，这是在所有接受该方案的患者中进行的肺扫描中检测到的。这些患者都没有临床症状。一名患者发生了无生命危险的二头肌血肿，可能是在rtPA治疗期间自动血压监测引起的。没有患者需要输血，也没有其他并发症发生。

The objective of the study is to evaluate thrombolytic therapy using recombinant tissue plasminogen activator (rtPA) for treatment of acute deep vein thrombosis of the lower extremity. While the conventional therapy, anticoagulation alone, is highly effective in prevention of life threatening pulmonary embolism, it does not preserve venous function in the affected leg, often leading to postphlebitic syndromes in subsequent years. The study is designed to evaluate efficacy, safety, and cost of this form of treatment for restoration of venous function in the lower extremity. Since start of the study, 14 patients have been treated. All except one patient had significant improvement. Only two patients have had evidence of small pulmonary emboli during treatment, detected on ventilation perfusion lung scans that are obtained in all patients accepted into the protocol. None of these patients were clinically symptomatic. One patient developed a non-life-threatening biceps hematoma probably induced by automatic blood pressure monitoring during the rtPA treatment. No patients have required blood transfusions and no other complications have occurred.